The Broken Big Pharma Blockbuster Business Model and the Future of Personalized Medicine
Disadvantages of Blockbuster Drugs: Rising Costs and Regulatory Hurdles
Blockbuster drugs, such as Lipitor, were designed to treat large, diverse populations, aiming to be equally effective across various patient groups. This universality has been a key driver of their financial success. However, achieving this broad efficacy is inherently challenging, as patients vary significantly in their genetics, lifestyle, and disease progression, leading to unpredictable responses to the same treatment. As a result, many new blockbuster drugs fail to deliver the expected outcomes, raising questions about their value relative to their high costs.
Additionally, regulatory and developmental hurdles for new drugs have intensified. The cost of bringing a new drug to market can exceed $2.6 billion. When considering patent protection, research, clinical trials, and regulatory approvals, these rising costs contribute to the higher prices of new treatments. Yet, these prices are increasingly scrutinized, especially when existing treatments offer comparable benefits at a lower price.
The Promise of Personalized Medicine: More Impact for Lower Costs
Personalized medicine, which tailors treatments to individual patients based on their genetic profiles and other specific factors, represents a significant departure from the one-size-fits-all approach of blockbuster drugs. Personalized therapies are designed for smaller, more targeted markets, reducing competition and extending investment repayment cycles. Interestingly, this shift could be highly lucrative for Big Pharma.
The precision of personalized medicine means treatments can be more effective and produce better patient outcomes. This enhanced efficacy can justify the higher prices of these specialized treatments. By demonstrating clear and superior health benefits, personalized drugs can command premium pricing, aligning with the value-based healthcare model increasingly favored by payers and providers. By targeting treatments to patients most likely to benefit, personalized medicine reduces the trial-and-error approach often associated with traditional therapies. This precision minimizes the overall burden on healthcare systems by decreasing ineffective treatments, adverse effects, and hospitalizations.
Manufacturing Challenges in Personalized Medicine (Which Are Also Advantages)
Transitioning to personalized medicine requires a fundamental change in manufacturing. Unlike traditional large-scale production, personalized therapies necessitate small-volume, multi-product facilities. These facilities need to be located closer to patients to enable rapid and customized production. Establishing this manufacturing infrastructure is time-consuming and capital-intensive, creating a significant barrier for generic competitors. While generic manufacturers have traditionally thrived on replicating blockbuster drugs at lower costs, reproducing personalized medicine setups poses a much greater challenge. The investment required to build these specialized facilities and develop the necessary expertise will likely slow the entry of generics into the personalized medicine market, giving Big Pharma a competitive edge.
A Sustainable Future for Big Pharma
I am convinced that the future of Big Pharma lies in embracing personalized medicine. This shift not only promises improved patient outcomes but also offers a sustainable business model at a time when the blockbuster drug approach is faltering. While the transition will require significant investment in new technologies and infrastructure, the long-term benefits for both patients and the industry are substantial. Personalized medicine stands to redefine the pharmaceutical landscape; if successful, it will make treatments more effective and align pricing with real-world outcomes—two goals well worth pursuing.
Prof. Dr. Ivan Lugovoi

Prof. Dr. Ivan Lugovoi is an Assistant Professor of Medical and Pharmaceutical Supply Chain Management at Kühne Logistics University. Prof. Dr. Ivan Lugovoi uses unique longitudinal datasets to study topics in operational management such as process innovation, procurement auctions, drug shortages, and standard setting. His work has been published in Manufacturing & Service Operations Management and Production and Operations Management.
You want even more?